

VIRAL INFECTIONS OF THE CENTRAL NERVOUS SYSTEM

Viral infections of the CNS are caused by a broad range of viruses.

MARCELLE ERASMUS, MB ChB, FCPATH SA (Viro)

Clinical Virologist, National Health Laboratory Services and University of Pretoria

Marcelle Erasmus recently qualified as a Clinical Virologist at the University of Pretoria and has a special interest in HIV with the focus on the genetic variability of the HIV virus.

Correspondence to: Marcelle Erasmus (marcelle.erasmus@up.ac.za)

References

1. Rice P. Viral meningitis and encephalitis. *Medicine* 2005;33:4.
2. Whitley RJ, Gnann JW. Viral encephalitis: familiar infections and emerging pathogens. *Lancet* 2002;359:507-513.
3. Stonehouse M, Gupta G, Wassmer E, et al. Acute disseminated encephalomyelitis: recognition in the hands of general paediatricians. *Arch Dis Child* 2003;88:122.
4. Noorbakhsh F, Johnson RT, Emery D, et al. Acute disseminated encephalomyelitis: clinical and pathogenesis features. *Neurol Clin* 2008;26:759-780.
5. Solomon T, Willison H. Infectious causes of acute flaccid paralysis. *Curr Opin Infect Dis* 2003;16:375.
6. Frohman EM, Wingerchuk DM. Transverse myelitis. *N Engl J Med* 2010;363(6):564-572.
7. Cinque P. Diagnosis of central nervous system complications in HIV-infected patients: cerebrospinal fluid analysis by the polymerase chain reaction. *AIDS* 1997;11:1.
8. Koralnik IJ. Progressive multifocal leukoencephalopathy revisited: has the disease outgrown its name? *Ann Neurol* 2006;60:162-173.
9. Boisse L, Gill MJ, Power C. HIV infection of the central nervous system: clinical features and neuropathogenesis. *Neurol Clin* 2008;26:799-819.
10. Singer EJ, Valdes-Sueiras M, Commins D, Levine A. Neurologic presentations of AIDS. *Neurol Clin* 2010;28(1):253-275.
11. Sever JL. Persistent measles infection of the central nervous system: subacute sclerosing panencephalitis. *Rev Infect Dis* 1983;5:467-473.
12. Sabella C. Measles: not just a childhood rash. *Cleve Clin J Med* 2010;77(3):207-213.
13. Johnson RT. Prion diseases. *Lancet Neurol* 2005;4:635-642.
14. McArthur JC, Brew BJ, Nath A. Neurological complications of HIV infection. *Lancet Neurol* 2005;4:543-555.
15. Kaplan JE, Osame M, Kubota H, et al. The risk of development of HTLV-I-associated myelopathy/tropical spastic paraparesis among persons infected with HTLV-I. *J Acquir Immune Defic Syndr* 1990;3:1096-10101.
16. Balisher WF. Reye syndrome and "Reye-like" diseases. In: Behrman, Kliegman, Jenson, eds. *Nelson textbook of pediatrics*. 16th ed. Philadelphia: WB Saunders Company, 2000: 1214-1216.
17. Wright BJ, Brew SL, Wesselingh SL. Pathogenesis and diagnosis of viral infections of the nervous system. *Neurol Clin* 2008;26:617-633.
18. Beaman MH, Wesselingh SL. Acute community-acquired meningitis and encephalitis. *Med J Aust* 2002;176(8):3893-3896.

CERVICAL CANCER SCREENING – A NEW VIRAL PARADIGM

Cervical cancer is the second most frequent cancer among women in South Africa (SA) and worldwide.

KARIN LOUISE RICHTER, MB ChB, FC (Path) Medical Virology, MMed (Path) Virology, Dip HIV Man, Dip Obst

Medical Virologist, Department of Medical Virology, University of Pretoria/National Health Laboratory Service, Pretoria

Karin Richter's fields of interest are infectious diseases with a focus on HIV, women's health issues and preventive medicine.

Correspondence to: Karin Richter (karin.richter@up.ac.za)

References

1. WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre). Human Papillomavirus and Related Cancers in South Africa. Summary Report 2010 Available at: www.who.int/hpvcentre (Accessed 19 January 2011).
2. Walboomers J, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. *J Pathol* 1999;89:12-19.
3. Merck. Monographs in medicine: Human papillomavirus. West Point, PA: Merck; 2008.
4. South African HPV Advisory Board. Cervical cancer and human papillomavirus: South African guidelines for screening and testing. *S Afr J Gynaecol Oncol* 2010;2(1):23-26.
5. Schiffman M, Castle PE. The Promise of Global Cervical-Cancer Prevention. *N Engl J Med* 2005;353(20):2010-2014.
6. Firnhaber CS, Michelow P. Cervical cancer and the human immunodeficiency virus: A review. *Southern African J HIV Med* 2009;10(2):23-27.
7. National Cancer Institute. National Cancer Institute surveillance epidemiology and end results. SEER stat fact sheet: cancer of the cervix uteri. Available at: <http://seer.cancer.gov> 2008 (Accessed 20 January 2011).
8. South African HPV Advisory Board. Testing for human papillomavirus in the diagnosis and follow-up of cervical cancer: Summary of revised guidelines for South Africa. *South Afr J Gynaecol Oncol* 2011 (in press).
9. Greenblatt RJ. Human papillomaviruses: disease, diagnosis, and a possible vaccine. *Clin Microbiol Newsl* 2005;27(18):139-145.
10. Nanda K, McCrory DC, Myers ER, et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review.

Ann Intern Med 2000;132:810-819.

11. Sherman ME, Lorincz AT, Scott DR, et al. Baseline cytology, human papillomavirus testing, and risk for cervical intraepithelial neoplasia: a 10-year cohort analysis. *J Natl Cancer Inst* 2003;95(1):46-52.
12. Dillner J, Rebolj M, Birembaut P, et al. Long term predictive values of cytology and HPV testing in cervical cancer screening: joint European cohort study. *BMJ* 2008;337:a1754.
13. South African Department of Health. National guideline on cervical cancer screening programme. Available at: <http://www.doh.gov.za/docs/factsheets/guidelines/cancer.pdf> (Accessed 25 January 2011).
14. Cuzick J. Long-term cervical cancer prevention strategies across the globe. *Gynecol Oncol* 2010;117:S11-14.
15. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin number 109, December 2009: cervical cytology screening. *Obstet Gynecol* 2009;114:1409-1420.
16. South African Department of Health. Clinical guidelines for the management of HIV & AIDS in adults and adolescents 2010. Available at: http://www.doh.gov.za/docs/factsheets/guidelines/adult_art.pdf (Accessed 28 April 2011).

HIV MANAGEMENT IN PRACTICE

South Africa has the largest HIV epidemic in the world and it is therefore imperative that all health care workers are knowledgeable about the management of HIV/AIDS.

THERESA M ROSSOUW, MB ChB, MPhil, MPH

Lead HIV Clinician, Tshwane-Metsweding area; Consultant, Department of Family Medicine, University of Pretoria (UP); and Researcher, Department of Immunology, UP

Theresa Rossouw completed her medical degree at Stellenbosch University. After working as a GP in Hout Bay she relocated to Pretoria, where she became head of the HIV Clinic at Tshwane District Hospital. She completed an MPhil and MPH and is involved in HIV research and mentoring, and doctoral studies in philosophy. Her current fields of interest are HIV resistance, especially the clinical relevance of low-frequency mutations and resistance after mother-to-child-transmission of HIV; and the concept and application of autonomy in clinical and research medicine.

Correspondence to: T Rossouw (theresa.rossouw@up.ac.za)

References

1. Global Report: UNAIDS Report on the Global AIDS Epidemic 2010. http://www.unaids.org/documents/20101123_GlobalReport_em.pdf (accessed 2 February 2011).
2. Brown D. As AIDS epidemic ebbs, many challenges remain. *Washington Post*, 23 November 2010. <http://www.washingtonpost.com/wp-dyn/content/article/2010/11/23/AR2010112304436.html> (accessed 2 February 2011).
3. Van Sighem A, Gras L, Reiss P, et al., on behalf of the ATHENA national observational cohort study. Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. *AIDS* 2010;24(10): 1527-1535.
4. South African National Department of Health. Clinical Guidelines for the Management of HIV and AIDS in Adults and Adolescents. Website of the South African National AIDS Council: www.sanac.org.za. (accessed 29 May 2010).
5. Antiretroviral Treatment of Adult HIV Infection. Recommendations of the International AIDS Society – USA Panel. 2010. *JAMA* 2010;340(3):321-333.
6. Siegfried N, Uthman OA, Rutherford GW. Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naïve adults. *Cochrane Database of Systematic Reviews* 2010, Issue 3. Art. No.: CD008272. DOI: 10.1002/14651858.CD008272.pub2.
7. Jonathan U, Armon C, Buchacz K, et al. The HOPS Investigators. Initiation of HAART at higher CD4 cell counts is associated with a lower frequency of antiretroviral drug resistance mutations at virological failure. *J Acquir Immune Defic Syndr* 2009;51:450-453.
8. Knobel H, Guelar A, Montero M, et al. Risk of side effects associated with the use of nevirapine in treatment-naïve patients, with respect to gender and CD4 cell count. *HIV Med* 2009;9(1):14-18.
9. Bruyand M, Thiebaut R, Lawson-Ayayi S, et al. Role of uncontrolled HIV RNA level and immunodeficiency in the occurrence of malignancy in HIV-infected patients during the combination antiretroviral therapy era: Agence Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort. *Clin Infect Dis* 2009;49:1109-1116.
10. Lawn SD, Myer L, Bekker L, Wood R. CD4 cell count recovery among HIV-infected patients with very advanced immunodeficiency commencing antiretroviral treatment in sub-Saharan Africa. *BMC Infectious Diseases* 2006;6:59.
11. Couper ID. Further reflections on chronic illness care. *SA Family Practice* 2007;49(4):4-10.
12. Brenner BL, Oliveira M, Doualla-Bell F, et al. HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. *AIDS* 2006;20(9):F9-F13.
13. Abdool Karim Q, Abdool Karim SS, Frohlich JA. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. *Science* 2010;329(5996):1168-1174.
14. Donnell D, Baeten JM, Kiari J. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. *Lancet* 2010;375 (9731):2092-2098.

MOSQUITO-BORNE VIRAL INFECTIONS IN SOUTHERN AFRICA: A PUBLIC HEALTH PERSPECTIVE

Of the six mosquito-borne viral infections of interest in Southern Africa, four can cause a haemorrhagic state.

P G D RAUTENBACH, BJuris, LLB, BA (Hons) Psychology, MB ChB, MMed (CIV), FCPHM (SA) (Occupational Medicine)
Professor and Head, Department of Public Health Medicine, University of Limpopo, Medunsa Campus, Pretoria

Professor Rautenbach is a member of the HIV Clinicians Society and the South African Society of Occupational Medicine. His current interests are health law and communicable diseases.

Correspondence to: P Rautenbach (peet@ul.ac.za)

References

1. Heyman DC, ed. Control of Communicable Diseases Manual. Washington: American Public Health Association, 2004:612-624.
2. World Health Organization. Fact sheets (Online). <http://www.who.int/mediacentre/factsheets> (accessed January 2011).
3. Webber R. Communicable Disease Epidemiology and Control. Cambridge: CAB International, 1997:3-21.
4. Cook GC, Zumla AI, eds. Manson's Tropical Diseases. London: Saunders, 2009:715-745.
5. Republic of South Africa. Regulations for Hazardous Biological Agents. Government Notice R1390: Government Gazette 22956, 27 December 2001.
6. Webber R. Communicable Disease Epidemiology and Control. Cambridge: CAB International, 1997:35-42.
7. Webber R. Communicable Disease Epidemiology and Control. Cambridge: CAB International, 1997:226.
8. Prinsloo B. Arboviral diseases in South Africa. SA Family Practice 2006;48(8):25-28.
9. World Health Organization. International Health Regulations (2005). Geneva: WHO, 2008.

WATER- AND FOODBORNE VIRUSES: CURRENT DEVELOPMENTS

Water and food are still major sources of enteric viruses.

MAUREEN B TAYLOR, BSc, BSc (Hons), MSc, DSc, Pr Sci Nat

Associate Professor/Senior Medical Scientist, Department of Medical Virology, Faculty of Health Sciences, University of Pretoria, and National Health Laboratory Service (NHLS), Tshwane Academic Division, Pretoria

Maureen Taylor's current fields of interest are food- and waterborne viruses, molecular epidemiology of enteric viruses, gastroenteritis viruses and enterically transmitted hepatitis viruses (A&E).

Correspondence to: Maureen Taylor (maureen.taylor@up.ac.za)

References

1. Gerba CP. Food Virology: Past, Present, and Future. In: Goyal SM, ed. Viruses in Foods. New York: Springer, 2006:1-4.
2. Widdowson M-A, Vinjé J. Food-borne viruses -- State of the Art. In: Koopmans MPG, Cliver DO, Bosch A, eds. Food-Borne Viruses: Progress and Challenges. Washington DC: ASM Press, 2008:29-64.
3. Grabow WOK. Overview of health-related water virology. In: Bosch A, ed. Human Viruses in Water. Amsterdam: Elsevier, 2007:1-25.
4. Koopmans M, von Bonsdorff C-H, Vinjé J, de Medici D, Monroe S. Foodborne viruses. FEMS Microbiol Rev 2002;26:187-205.
5. Verhoef LPB, Kroneman A, van Duynhoven Y, Boshuizen H, van Pelt W, Koopmans M on behalf of the Foodborne Viruses in Europe Network. Selection tool for foodborne norovirus outbreaks. Emerg Infect Dis 2009;15:31-38.
6. Koopmans M, Duizer E. Foodborne viruses: an emerging problem. Int J Food Microbiol 2004;90:23-41.
7. Sobsey MD. Drinking water and health research: a look to the future in the United States and globally. J Water Health 2006;4[Suppl]:17-21.
8. Ashbolt NJ. Microbial contamination of drinking water and disease outcomes in developing regions. Toxicology 2004;198:229-238.
9. O'Brein SJ. The challenge of estimating the burden of an underreported disease. In: Koopmans MPG, Cliver DO, Bosch A, eds. Food-Borne Viruses: Progress and Challenges. Washington DC: ASM Press, 2008:87-115.
10. Taylor MB, Becker PJ, Janse van Rensburg E, Harris BN, Bailey I, Grabow WOK. A serosurvey of waterborne pathogens amongst canoeists in South Africa. Epidemiol Infect 1995;115:299-307.
11. Taylor MB, Schildhauer CI, Parker S, et al. Two successive outbreaks of SRSV associated gastroenteritis in South Africa. J Med Virol 1993;41:18-23.
12. Bosch A, Sánchez G, Abbaszadegan M, et al. Analytical methods for virus detection in water and food. Food Anal Methods 2011;4:4-12.
13. Zheng DP, Ando T, Fankhauser RL, Beard RS, Glass RI, Monroe SS. Norovirus classification and proposed strain nomenclature. Virology 2006;346:312-323.
14. Atmar RL. Noroviruses: State of the art. Food Environ Virol 2010;2:117-126.
15. Patel MN, Hall HJ, Vinjé J, Parashar UD. Noroviruses: A comprehensive review. J Clin Virol 2009;44:1-8.
16. Mans J, de Villiers JC, du Plessis N, Avenant T, Taylor MB. Emerging norovirus GII.4 2008 variant detected in hospitalised paediatric patients in South Africa. J Clin Virol 2010;49:258-264.

17. Pintó RM, Costafreda MI, Pérez-Rodríguez J, D'Andrea L, Bosch A. Hepatitis A virus: State of the art. *Food Environ Virol* 2010;2:127-135.
18. Aggarwal R, Naik S. Enterically transmitted hepatitis. In: Koopmans MPG, Cliver DO, Bosch A, eds. *Food-Borne Viruses: Progress and Challenges*. Washington DC: ASM Press, 2008:65-85.
19. Hollinger FB, Emerson SU. Hepatitis A virus. In: Knipe DM, Howley PM, Griffen DE, et al., eds. *Fields Virology*. 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2007:911-947.
20. Taylor MB. Molecular epidemiology of South African strains of hepatitis A virus: 1982-1996. *J Med Virol* 1997;51:273-279.
21. Venter JME, van Heerden J, Vivier JC, Grabow WOK, Taylor MB. Hepatitis A virus in surface water in South Africa: What are the risks? *J Water Health* 2007;5:229-240.
22. NICD guidelines for the control of hepatitis A in South Africa. Available from: URL: <http://www.nicd.ac.za/>
23. Mattison K, Bidawid S. Analytical methods for food and environmental viruses. *Food Environ Virol* 2009;1:107-122.

CURRENT LABORATORY DIAGNOSIS OF HEPATITIS B VIRUS INFECTION INCLUDING 8 YEARS OF RETROSPECTIVE LABORATORY DATA

Hepatitis B is far more infectious than HIV.

S M BOWYER, BSc (Hons), MSc (Med), PhD, Dip Dat

Senior Medical Scientist and Senior Lecturer, Department of Medical Virology, University of Pretoria

Dr Sheila Bowyer is passionate about the molecular biology and evolution of the hepatitis viruses and has a penchant for hepatitis B. She also enjoys turning raw data into visually palatable information using the myriad of available bioinformatics tools.

J G M SIM, BSc, MB ChB, MMed (Virol), DTM&H

Clinical Pathologist, Drs Martin & Sim Inc., Clinical Pathologists, Toga Laboratories, Johannesburg

Dr John Sim has had a long-term research interest in the hepatitis viruses. In 1999 he was a driving force behind the establishment of the Toga Pathology Laboratories which specialise in affordable, cutting-edge, molecular diagnostic techniques aimed, in particular, at combating the HIV epidemic.

L M WEBBER, MB ChB, MMed Path (Virol), DTH

Head, Department of Medical Virology, University of Pretoria

Professor Lynne Webber has research interests in blood-borne viruses, which mostly include HIV, hepatitis B and hepatitis C viruses. A number of research initiatives are taking place within the oral, facial and maxillo-surgery settings and the forensic medicine disciplines.

Corresponding author: S Bowyer (sheila.bowyer@up.ac.za)

References:

1. CDC. Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure prophylaxis. *Mor Mortal Wkly Rep* 2001;50(No RR-11):1-52. (<http://www.aegis.com/pubs/mmwr/2001/RR5011a1.html>)
2. World Health Organisation, Department of Communicable Diseases, Surveillance and Response. WHO/CDS/CSR/LYO/2002.2: Hepatitis B. 2002. (http://www.who.int/csr/disease/hepatitis/HepatitisB_whoedscsrlyo2002_2.pdf)
3. Gitlin N. Hepatitis B: diagnosis, prevention, and treatment. *Clin Chem* 1997;43:1500-1506.
4. Szymaragd C, et al. Genome-wide characterisation of hepatitis B mutations involved in clinical outcome. *Heredity* 2006;97(6):389-397.
5. Hoofnagle JH, et al. Management of hepatitis B: summary of a clinical research workshop. *Hepatology* 2007;45(4):1056-1075.
6. McMahon BJ. Natural history of chronic hepatitis B -- clinical implications. *Medscape J Med* 2008;10(4):91.
7. Sim JGM. Hepatitis B virus serology: eight years of laboratory data in retrospect. Johannesburg: University of the Witwatersrand, 1993.
8. Whiteside A, Sunter C. AIDS: The challenge for South Africa. In: Rousseau HA, ed. Cape Town: Tafelberg, 2000.
9. Van der Vliet, V. South Africa divided against AIDS: a crisis of leadership In: Kaufman K, Lindauer D, eds. *AIDS and South Africa: The Social Expression of a Pandemic*. Handmills, Basingstone, Hampshire, England: Palgrave Macmillan, 2004.
10. Draeos M, et al. Significance of isolated antibody to hepatitis B core antigen determined by immune response to hepatitis B vaccination. *JAMA* 1987;258(9):1193-1195.
11. Brechot C, et al. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"? *Hepatology* 2001;34(1):194-203.
12. Kew MC, Welschinger R, Viana R. Occult hepatitis B virus infection in Southern African blacks with hepatocellular carcinoma. *J Gastroenterol Hepatol* 2008;23(9):1426-1430.
13. Puoti M, et al. Natural history of chronic hepatitis B in co-infected patients. *J Hepatol* 2006;44(1 Suppl):S65-70.
14. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. *Hepatology* 2009;50(3):661-662.
15. Kramvis A, et al. Nucleic acid sequence analysis of the precore region of hepatitis B virus from sera of southern African black adult carriers of the virus. *Hepatology* 1997;25:235-240.

MORE ABOUT... MEDICAL VIROLOGY

Human papillomavirus (HPV) vaccines

ADELE VISSER, MB CHB, DTM&H, PG DIP TM

Senior Registrar, Division of Clinical Pathology, Faculty of Health Sciences, University of Pretoria, and National Health Laboratory Service (NHLS), Tshwane Academic Division, Pretoria

ANWAR HOUSEN, MSc, MB ChB, MMed, FCPATH (Med Micro)

Chief Specialist and Professor, Department of Medical Microbiology, Faculty of Health Sciences, University of Pretoria, and National Health Laboratory Service (NHLS), Tshwane Academic Division, Pretoria

Correspondence to: Adele Visser (adele.vis@gmail.com)

References

1. Sinanovic E, Moodley J, Barone M, Mall S, Cleary S, Harries J. The potential cost-effectiveness of adding a human papilloma vaccine to the cervical cancer screening programme in South Africa. *Vaccine* 2009;27:6396-6402.
2. Harries J, Moodley J, Barone M, Mall S, Sinanovic E. Preparing for HPV vaccination in South Africa: Key challenges and opinions. *Vaccine* 2009;27:38-44.
3. Torre GL, Waure Cd, Chiaradia G, Mannocci A, Ricciardi W. HPV vaccine efficacy in preventing persistent cervical HPV infection: A systematic review and meta-analysis. *Vaccine* 2007;25:8352-8358.
4. WHO. WHO position on HPV vaccines. In: *Biologicals DoIVA*, ed. Geneva: *Vaccine* 2009, p. 7236-7.
5. Stanely M, Lowy D, Frazer I. Chapter 12: Prophylactic HPV vaccines: Underlying mechanisms. *Vaccine* 2006;24S3:S3-106-13.
6. WHO. Conclusion: Moderate quality of scientific evidence to support HPV vaccination of young adolescent girls to prevent cervical cancer later in life. http://www.who.int/immunization/HPV_Grad_Adol_girls.pdf (accessed 2009 April 2009)
7. Agorastos T, Chatzigeorgiou K, Brotherton L, Garland S. Safety of human papillomavirus (HPV) vaccines: A review of the international experience so far. *Vaccine* 2009;27:7270-7281.
8. Markowitz L, Dunne E, Saraiya S, Lawson H, Chesson H, Unger E. Quadrivalent Human Papillomavirus Vaccine: recommendations of the Advisory Committee on Immunization and Practices (ACIP). *MMWR* 2007;56(Mar 23):1-24.
9. Markowitz L, Hariri S, Unger E, Saraiya M, Datta S, Dunne E. Post-licensure monitoring of HPV vaccine in the United States. *Vaccine* 2010;28:4731-4737.
10. Palefsky J, Gillison M, Strickler H. Chapter 16: HPV vaccines in immunocompromised women and men. *Vaccine* 2006;24S3:S3/140-6.
11. Dochez C, Veen Fvd, Meheus A. HPV vaccines and prevention of cervical cancer. *BJMO* 2009;3(6):275-281.
12. Villa L. Prophylactic HPV vaccines: Reducing the burden of HPV-related disease. *Vaccine* 2006;24(S1):23-28.
13. Wong LP. Physicians' experience with HPV vaccine delivery: Evidence from developing country with multiethnic populations. *Vaccine* 2009;27:1622-1627.

Infection prevention and control for viral infections

RUTH LEKALAKALA, BSc, MB ChB, DTM&H, MMED (Medical Microbiology), PDIC

Consultant Medical Microbiologist, Principal Pathologist and Senior Lecturer, Department of Medical Microbiology, Faculty of Health Sciences, University of Pretoria and Tshwane Academic Division, National Health Laboratory Service (NHLS)

Correspondence to: Ruth Lekalakala (ruth.lekalakala@up.ac.za)

References

1. World Health Organization. Advice on the use of masks in the community setting in Influenza A (H1N1) outbreaks. Interim guidance (3 May 2009), 2009. (<http://www.who.int/csr/resources/publications/Adviceuse>)
2. Lee A, Chuh AAT. Facing the threat of influenza pandemic: roles of and implications to general practitioners. *BMC Public Health* 2010;10:661.
3. Siegel JD, et al. Guideline for isolation precautions: preventing transmission of infectious agents in health care settings, June 2007. Atlanta, Georgia: Public Health Service, US Department of Health and Human Services, Centres for Disease Control and Prevention. <http://www.cdc.gov/ncidod/dhqp/pdf/isolation2007.pdf>
4. Craig AT, Kasai T, Li A, Otsu S, Khut QY. Getting back to basics during a public health emergency: a framework to prepare and respond to infectious disease public health emergencies. *Public Health* 2010;124:10-13.
5. Mehtar S. *Understanding Infection Prevention*. Cape Town: South Africa: Juta & Company, 2010
6. Center for Disease Control. Interim Infection Control Recommendations for Care of Patients with Suspected or Confirmed Filovirus (Ebola, Marburg) Hemorrhagic Fever. BDP/EPR/WHO, Geneva, 2008.